Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

UK bans parallel exporting of crucial medicines to help COVID-19 patients

20
SHARES

The UK government has announced that the parallel export of certain essential medicines is banned, to preserve drugs for the treatment of coronavirus patients.

Pile of medicines

…the restrictions are a standard measure to manage potential medicine shortages”

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The UK government has announced that crucial medicines are to be protected for COVID-19 coronavirus patients; more than 80 medicines used to treat patients in intensive care units have been banned from parallel export* from the UK.

According to the government, the parallel export ban will help to ensure there is an uninterrupted supply of medicines for National Health Service (NHS) hospitals treating coronavirus patients.

The new restrictions cover crucial medicines such as:

  • adrenaline
  • insulin
  • paracetamol
  • morphine.

The government emphasises that the restrictions are a standard measure to manage potential medicine shortages and protects UK patients by ensuring the NHS has the treatments to continue providing their care.

Companies that parallel export a medicine on the ban list may face tough enforcement action from the Medicines and Healthcare products Regulatory Agency (MHRA) and risk having their trading licence revoked for serious breaches. Furthermore, the Department of Health and Social Care has existing processes to deal with and resolve medicines shortages. 

India to restrict 10 percent of medicine exports due to coronavirus…

Health minister Lord James Bethell said: “Our brilliant NHS staff are going above and beyond to provide world-class care to patients with coronavirus and we are supporting them in every way we can. We are today banning the parallel export of more than 80 crucial medicines to protect patients in the UK and help ensure they can always get the treatments they need.”

The full list of medicines that cannot be parallel exported from the UK can be found here. 

*Parallel exporting is when companies buy medicines meant for UK patients and sell on for a higher price in another country, potentially causing or aggravating supply problems.

2 responses to “UK bans parallel exporting of crucial medicines to help COVID-19 patients”

  1. ruby Osman says:
    22 April 2020 at 3:08 pm

    Hi Staff, I missed the A 360 overview of data integrity in life sciences webinar on 21/04/ would you please advice ac I would like to have listen to the webinar.

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Share via
Share via